- Home
- CBLL vs REPL Comparison
CBLL vs REPL Comparison
Compare CBLL & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBLL
- REPL
- Stock Information
- Founded
- CBLL 2014
- REPL 2015
- Country
- CBLL United States
- REPL United States
- Employees
- CBLL N/A
- REPL N/A
- Industry
- CBLL
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- CBLL
- REPL Health Care
- Exchange
- CBLL Nasdaq
- REPL Nasdaq
- Market Cap
- CBLL 927.1M
- REPL 780.3M
- IPO Year
- CBLL 2024
- REPL 2018
- Fundamental
- Price
- CBLL $21.04
- REPL $10.14
- Analyst Decision
- CBLL Strong Buy
- REPL Strong Buy
- Analyst Count
- CBLL 5
- REPL 6
- Target Price
- CBLL $33.25
- REPL $17.50
- AVG Volume (30 Days)
- CBLL 320.4K
- REPL 794.9K
- Earning Date
- CBLL 02-14-2025
- REPL 02-06-2025
- Dividend Yield
- CBLL N/A
- REPL N/A
- EPS Growth
- CBLL N/A
- REPL N/A
- EPS
- CBLL N/A
- REPL N/A
- Revenue
- CBLL $60,041,000.00
- REPL N/A
- Revenue This Year
- CBLL $44.86
- REPL N/A
- Revenue Next Year
- CBLL $26.56
- REPL $300.41
- P/E Ratio
- CBLL N/A
- REPL N/A
- Revenue Growth
- CBLL 131.62
- REPL N/A
- 52 Week Low
- CBLL $18.69
- REPL $4.92
- 52 Week High
- CBLL $32.75
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- CBLL N/A
- REPL 32.06
- Support Level
- CBLL N/A
- REPL $10.00
- Resistance Level
- CBLL N/A
- REPL $11.20
- Average True Range (ATR)
- CBLL 0.00
- REPL 0.84
- MACD
- CBLL 0.00
- REPL -0.20
- Stochastic Oscillator
- CBLL 0.00
- REPL 3.93
About CBLL CeriBell Inc. Common Stock
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.